Prostate Cancer News

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of prostate cancer treatment and survivorship.

Share

Prostate Cancer News


Radiation Therapy Benefits Selected Patients With Node-Positive Prostate Cancer (October 13, 2014)

According to a recent report published in The Journal of Clinical Oncology, men with advanced prostate cancer involving the lymph nodes may benefit from treatment with radiation in addition to hormonal... Continue Reading

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients (October 1, 2014)

REDWOOD CITY, Calif., Sept. 29, 2014 – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX®... Continue Reading

Advances in Genomic Testing-What you Need to Know (September 29, 2014)

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and... Continue Reading

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (September 18, 2014)

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor... Continue Reading

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (September 15, 2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine. ... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed... Continue Reading

Cabozantinib Development in Prostate Cancer Halted (September 3, 2014)

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal... Continue Reading

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer (August 27, 2014)

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

More Prostate Cancer News

Latest Prostate Cancer News By Stage


Screening and Prevention

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

PSA Testing May Be Appropriate for Some Men (July 25, 2012)

The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading

Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)

Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading

More Screening and Prevention

Early Stage I-II (A-B)

Radiation Therapy Benefits Selected Patients With Node-Positive Prostate Cancer (October 13, 2014)

According to a recent report published in The Journal of Clinical Oncology, men with advanced prostate cancer involving the lymph nodes may benefit from treatment with radiation in addition to hormonal therapy. Prostate cancer is the most commonly diagnosed... Continue Reading

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients (October 1, 2014)

REDWOOD CITY, Calif., Sept. 29, 2014 – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with... Continue Reading

Advances in Genomic Testing-What you Need to Know (September 29, 2014)

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and predict the behavior of certain tissues within... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

More Early Stage I-II (A-B)

Locally Advanced Stage III (C)

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

More Locally Advanced Stage III (C)

Metastatic Stage IV (D)

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (September 15, 2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

Cabozantinib Development in Prostate Cancer Halted (September 3, 2014)

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase... Continue Reading

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer (August 27, 2014)

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab... Continue Reading

More Metastatic Stage IV (D)

Refactory/Recurrent

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (September 18, 2014)

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment... Continue Reading

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer (September 15, 2014)

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012... Continue Reading

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives (September 11, 2014)

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs)... Continue Reading

September Brings Awareness to Prostate Cancer (September 4, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of prostate cancer programs for national prostate cancer awareness month.  Prostate cancer is the most frequently diagnosed cancer in men and is a leading cause of cancer... Continue Reading

Cabozantinib Development in Prostate Cancer Halted (September 3, 2014)

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase... Continue Reading

<More Refactory/Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS